secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001628280-25-058729
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab
--------------------------------------------------------------------------------

- Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
- Halozyme to be exclusive supplier of clinical and commercial rHuPH20 API for the product.
- Milestone payments tied to development, commercialization, and net sales levels; mid-single digit royalties on worldwide net sales.
- Agreement includes customary termination rights, reps, warranties, and indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828025058729/0001628280-25-058729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828025058729/skye-20251218.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-058729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer